Bionano To Present Optical Genome Mapping Utility Across Cancer Research Applications At The CGC 2024 Annual Meeting

Author: Benzinga Newsdesk | August 01, 2024 08:09am

• A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women's Hospital presenting data from a multi-site study evaluating the performance and benefits of optical genome mapping (OGM) in comparison to classical methods for hematological malignancies
  
   
• Two scientific poster presentations from researchers at Vancouver General Hospital and Dartmouth Hitchcock Medical Center will illustrate the application of Bionano's OGM workflow in blood cancer research
• Three scientific posters featuring results from OGM applications in cancer will be on display at the conference
  
   

SAN DIEGO, August 1, 2024 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for hematological malignancy cancer research, including scientific poster presentations and an exhibitor session featuring data from a multi-site study evaluating OGM's utility for evaluating hematological malignancies.

Posted In: BNGO